EVO
Price
$4.55
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
133 days until earnings call
LFCR
Price
$7.09
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
49 days until earnings call
Ad is loading...

EVO vs LFCR

Header iconEVO vs LFCR Comparison
Open Charts EVO vs LFCRBanner chart's image
Evotec SE
Price$4.55
Change-$0.00 (-0.00%)
Volume$92.82K
CapitalizationN/A
Lifecore Biomedical
Price$7.09
Change-$0.00 (-0.00%)
Volume$208.62K
CapitalizationN/A
EVO vs LFCR Comparison Chart
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
EVO vs. LFCR commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Buy and LFCR is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (EVO: $4.55 vs. LFCR: $7.09)
Brand notoriety: EVO and LFCR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVO: 54% vs. LFCR: 126%
Market capitalization -- EVO: $2.77B vs. LFCR: $176.87M
EVO [@Pharmaceuticals: Other] is valued at $2.77B. LFCR’s [@Pharmaceuticals: Other] market capitalization is $176.87M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, both EVO and LFCR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 6 TA indicator(s) are bullish while LFCR’s TA Score has 6 bullish TA indicator(s).

  • EVO’s TA Score: 6 bullish, 4 bearish.
  • LFCR’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, LFCR is a better buy in the short-term than EVO.

Price Growth

EVO (@Pharmaceuticals: Other) experienced а +17.72% price change this week, while LFCR (@Pharmaceuticals: Other) price change was +10.61% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +58.13%. For the same industry, the average monthly price growth was -5.12%, and the average quarterly price growth was -10.17%.

Reported Earning Dates

EVO is expected to report earnings on Mar 27, 2025.

LFCR is expected to report earnings on Jan 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+58.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($2.77B) has a higher market cap than LFCR($177M). LFCR YTD gains are higher at: 14.540 vs. EVO (-61.211). LFCR has higher annual earnings (EBITDA): -22.64M vs. EVO (-63.26M). EVO has more cash in the bank: 619M vs. LFCR (4.22M). LFCR has less debt than EVO: LFCR (157M) vs EVO (589M). EVO has higher revenues than LFCR: EVO (821M) vs LFCR (188M).
EVOLFCREVO / LFCR
Capitalization2.77B177M1,564%
EBITDA-63.26M-22.64M279%
Gain YTD-61.21114.540-421%
P/E Ratio476.19N/A-
Revenue821M188M437%
Total Cash619M4.22M14,661%
Total Debt589M157M375%
FUNDAMENTALS RATINGS
EVO vs LFCR: Fundamental Ratings
EVO
LFCR
OUTLOOK RATING
1..100
2915
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
4338
P/E GROWTH RATING
1..100
26
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LFCR's Valuation (92) in the Industrial Specialties industry is in the same range as EVO (97) in the null industry. This means that LFCR’s stock grew similarly to EVO’s over the last 12 months.

LFCR's Profit vs Risk Rating (100) in the Industrial Specialties industry is in the same range as EVO (100) in the null industry. This means that LFCR’s stock grew similarly to EVO’s over the last 12 months.

EVO's SMR Rating (92) in the null industry is in the same range as LFCR (97) in the Industrial Specialties industry. This means that EVO’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's Price Growth Rating (38) in the Industrial Specialties industry is in the same range as EVO (43) in the null industry. This means that LFCR’s stock grew similarly to EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is in the same range as LFCR (6) in the Industrial Specialties industry. This means that EVO’s stock grew similarly to LFCR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOLFCR
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 10 days ago
66%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend about 1 month ago
76%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
EVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AAGPX27.000.01
+0.04%
American Beacon Large Cap Value Inv
GGWPX13.95N/A
N/A
Goldman Sachs Global Infras P
RAFFX47.37-0.06
-0.13%
American Funds AMCAP R5
NRIFX21.75-0.06
-0.28%
Nuveen Real Asset Income R6
HSLIX52.73-0.44
-0.83%
Hartford Small Cap Growth I

EVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
+2.48%
SNDL - EVO
42%
Loosely correlated
-1.75%
LFCR - EVO
29%
Poorly correlated
+1.00%
ACET - EVO
26%
Poorly correlated
-5.17%
ESPR - EVO
25%
Poorly correlated
-8.23%
AMPH - EVO
23%
Poorly correlated
-4.70%
More

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+1.00%
SHPH - LFCR
31%
Poorly correlated
-2.69%
CRON - LFCR
29%
Poorly correlated
-3.98%
CGC - LFCR
28%
Poorly correlated
N/A
TLRY - LFCR
27%
Poorly correlated
-1.70%
OGI - LFCR
26%
Poorly correlated
-0.63%
More